Quantcast

Latest hyperphosphatemia Stories

2009-11-04 07:30:00

NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Merriman Curhan Ford 6th Annual Investor Summit being held in New York City. Mr. Bentsur's presentation will be webcast live on Tuesday, November 10th at 3:40 pm ET and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of...

2009-10-29 07:30:00

NEW YORK, Oct 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference taking place November 3-4, 2009 at the Waldorf=Astoria in New York City. Mr. Bentsur's presentation will be webcast live on Wednesday, November 4th at 4:30PM ET and will be accessible from the Investor Information page of the Company's Website at...

2009-10-26 07:30:00

NEW YORK, Oct. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that an abstract related to the clinical data of the 55-patient Phase 2 high-dose study of Zerenex (ferric citrate) has been accepted for presentation during the poster sessions to be held at the upcoming American Society of Nephrology (ASN) Renal Week Meeting and exposition taking place October 27-November 1 in San Diego, California. Poster Number: PO-361, entitled "Evaluation of...

2009-09-23 07:30:00

NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced results of the Open Label Extension (OLE) trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The OLE trial, conducted in Taiwan, enrolled 29 of the 37 Taiwanese patients that had completed the randomized, multi-center, multi-national (United States and Taiwan)...

2009-08-04 15:30:00

NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Thursday, August 6, 2009 at 8:30 a.m. EDT to discuss the second quarter 2009 financial results and business outlook for the remainder of 2009. Ron Bentsur, Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call,...

2009-06-08 07:30:00

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis. The study was a multicenter, open-label clinical trial, which enrolled 55 patients. The primary objective of this study was to assess the tolerability and safety of Zerenex...

2009-04-23 15:30:00

NEW YORK, April 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Michael P. Tarnok to be its interim Chairman and Chief Executive Officer, replacing Michael S. Weiss, effective immediately. Mr. Tarnok, age 54, has served on Keryx's Board of Directors since September 2007. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director -- US Manufacturing. From 2000-2007, Mr. Tarnok served...

2008-12-01 19:55:00

EXTON, Pa., Dec. 1 /PRNewswire/ -- BioTrends Research Group, Inc. released its third TreatmentTrends(TM): European Nephrology Report. This report runs parallel to two ongoing studies BioTrends conducts -- TreatmentTrends(TM): US and Canadian Nephrology. The report is based on the results of an on-line survey completed by 200 Nephrologists from the UK, Germany, France, Italy, and Spain. The focus is on the management of renal anemia and hyperphosphatemia. In the ESA market, Amgen's Aranesp...

2008-11-06 11:17:34

MARKHAM, Ontario, Nov. 6 /PRNewswire/ -- Cytochroma today announced positive comparative data on a novel vitamin D analog, CTA018, at the 2008 Annual Meeting of the American Society of Nephrology (ASN) in Philadelphia. In preclinical models, CTA018 has demonstrated advantages over two marketed vitamin D hormone replacement therapies, calcitriol and paricalcitol (Zemplar(R)), the latter currently being the most widely used therapy for secondary hyperparathyroidism (SHPT) in the United States...

2008-04-03 12:01:03

PHILADELPHIA, April 3, 2008 /PRNewswire/ -- Shire Pharmaceuticals, the global biopharmaceutical company, today announced the launch of On Track, an innovative program designed to improve adherence to disease management regimens among chronic kidney disease (CKD) Stage 5 patients with hyperphosphatemia (elevated levels of phosphorus in the blood). In addition to offering the highly effective phosphate binder, FOSRENOL (lanthanum carbonate), Shire has created On Track, a program designed to...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related